Allyx Therapeutics aims to deliver a novel approach

to preserve and protect synapses

for people living with neurodegenerative diseases

Latest News from Allyx

June 11, 2024

Allyx Therapeutics Announces First Alzheimer’s Disease Patient Treated with Lead Compound ALX-001

March 5, 2024

Allyx Therapeutics Announces Expansion into Parkinson’s Disease Clinical Research with Lead Compound ALX-001 Following IND Acceptance

October 30, 2023

Allyx Therapeutics releases top-line Phase 1a data for ALX-001, demonstrating oral administration is safe and well-tolerated at all doses and achieves full brain receptor occupancy.